RE:RE:RE:RE:ONCY bispecific in development (pelareorep x CD3)The combination of BiTEs/TriTEs with OVs holds the potential for mutual advantages.
"Reovirus and bispecific antibodies are a true tumor-killer combo that would not be effective without each other.” - Dr. Nadine van Montfoort, group leader of viro-immunotherapy of cancer – at the Leiden University Medical Center (LUMC) in the Netherlands.
Instead of directly focusing on cancer cells, BiTEs have the potential to be engineered in a manner that enables T cells to be directed towards pro-tumorigenic factors within the TME.
Due to BiTEs/TriTEs limitations in solid tumor treatments, the use of BiTE- or TriTE in combination with ONCY's pelareorep poses an attractive and efficient approach for addressing this unresolved clinical requirement, especially when employed in combination with supplementary methods aimed at mitigating the immunosuppressive tumor microenvironment.